Back to All

The depth of the data on DXRX-The Diagnostic Network® enables a launch strategy that leaves no patient behind

6 April, 2021

It is important for pharmaceutical companies in the Precision Medicine space not to underestimate the level of complexity involved in the companion diagnostic aspect to asset performance in the market once approval is received. Clinical application of companion diagnostic dependent therapeutics is riddled with challenges1. To forget about the companion diagnostic strategy required to deliver these therapeutics to the right patients, means these companies are risking missing up to 50% of the patient population whose lives they are seeking to improvewith their innovations.

Diaceutics launched DXRX-The Diagnostic Network®to solve the broken diagnostic ecosystem by addressing the core problem in diagnostic care, its fragmentation, by integrating the key stakeholders involved in diagnostic care in a secure digital platform holding the largest repository of testing data. DXRX enables access to 365+ million de-identified patient records in 53 countries.

The DXRX platform’s data coverage contains:

  • 4.7 years’ longitudinal history
  • 12,717 labs showing disease volumes
  • 493 labs providing results data
  • 9,500 payors globally
  • Data available from 2011
  • Combined coverage from academic, community & reference labs

DXRX contains additional features for the US market:

  • Weekly data feeds with 2-day lag
  • 64% coverage of patients
  • 670,000 referring physicians
  • 6 of top 10 reference labs   

Pharmaceutical companies with a development pipeline in Precision Medicine are wise to inform their strategy by evidence from data sources with this level of depth, to avoid delaying innovations reaching the patients for whom they are meant to improve the outcomes, as it can take up to 4.5 years for a biomarker test to be developed and it takes up to 3 years for over 70% of labs to get ready to offer a new biomarker test. These timelines are underscoring the need to start on time with the companion diagnostic strategy to deliver innovation to the right patient at the right time.

Access to data with this level of data coverage on DXRX-The Diagnostic Network® will provide a better understanding of a patient’s diagnostic journey from diagnosis to treatment decision in the indication of interest, even if patients move from lab to lab, through data points around: 

  • Testing events
  • Test results
  • Test sequence
  • Stage of disease

The depth of the data coverage on DXRX not only enables evidence-based decisions for the diagnostic strategy of precision therapeutics as earlier described4 but it also accelerates clinical trial enrolment by identifying eligible patients through its lab network, making sure no patient who can benefit from precision therapeutics is left behind!

If your therapeutic is on the market and still not reaching all the patients it is meant to benefit or you are preparing to launch a therapeutic, tell us about your project!


  1. Challenges in the clinical implementation of precision medicine companion diagnostics - Diaceutics
  3. Diaceutics launches world’s first Diagnostic Network for Precision Medicine to solve global cancer testing issues - Diaceutics
  4. Patient access to innovations in Precision Medicine accelerated by an evidence-based strategy to launch - Diaceutics

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny